



PRESS RELEASE

Submitted for disclosure on 18 October 2016 at 12.00 (CET).

The information in this press release is not intended for distribution, publication or public release, directly or indirectly, in or into Australia, Canada, Japan, the United States or any other jurisdiction where the publication or distribution of this press release may be unlawful.

Probi publishes prospectus supplement

Probi AB (publ) (“Probi”) has prepared a prospectus supplement in addition to the prospectus which was approved and registered by the Swedish Financial Supervisory Authority on 4 October 2016 regarding invitation to subscribe for shares in the company and published on the same day. The prospectus supplement has been prepared by reason of the company’s interim report for the period 1 January 2016 – 30 September 2016, which Probi published on 18 October 2016.

The prospectus supplement was approved and registered by the Swedish Financial Supervisory Authority on 18 October 2016 and is available on Probi’s website www.probi.com and on the Swedish Financial Supervisory Authority’s website www.fi.se. The prospectus supplement forms part of, and must be read together with, the prospectus.

Investors who, prior the publication of this prospectus supplement, have applied for or otherwise given their consent to subscription of shares in Probi’s rights issue have, pursuant to chapter 2, section 34 of the Swedish Financial Instruments Trading Act (SFS 1991:980), the right to withdraw their application or consent within two working days from the publication of the prospectus supplement. Consequently, the last day for withdrawal is 20 October 2016. Withdrawal shall be made by a written notice to Handelsbanken Capital Markets, Emission, SE-106 70 Stockholm, Sweden. Investors who have applied for subscription of new shares in the rights issue through a nominee shall contact their nominee regarding withdrawal. Applications that are not withdrawn will remain binding and investors who want to maintain their subscription of shares in the rights issue do not need to take any action. For detailed terms and conditions as well as other information about the rights issue, please refer to the prospectus.

FOR FURTHER INFORMATION, CONTACT:

Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23, e-mail: peter.nahlstedt@probi.se
Niklas Brandt, CFO, Probi, tel +46 46 286 89 26, e-mail: niklas.brandt@probi.se

ABOUT PROBI

Probi AB is a Swedish publicly traded bioengineering company that develops effective and well-documented probiotics. Through its world-leading research, Probi has created a strong product portfolio in the gastrointestinal health and immune system niches. Probi’s products are available to consumers in more than 30 countries worldwide. Probi’s customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. In 2015 Probi had sales of MSEK 216. The Probi share is listed on Nasdaq Stockholm, Small Cap. Probi has about 4,400 shareholders. Read more at www.probi.se.



IMPORTANT NOTICE

The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in Probi. Any invitation to the persons concerned to subscribe for shares in Probi is only made through the prospectus which Probi published on 4 October 2016.

This press release may not be released, published or distributed, directly or indirectly, in or into Australia, Japan, Canada, the United States or any other jurisdiction where participation would require additional prospectuses, registration or measures besides those required by Swedish law. Nor may this press release be distributed in or into such countries or any other country or jurisdiction in which distribution requires such measures or otherwise would be in conflict with applicable regulations. Any failure to comply with the restrictions described may result in a violation of applicable securities regulations.

No subscription rights, paid subscribed shares or shares in Probi have been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act") or the securities legislation of any state or other jurisdiction in the United States and no subscription rights, paid subscribed shares or shares may be offered, subscribed for, sold, resold, delivered or otherwise transferred, directly or indirectly, in or into the United States except under an available exemption from, or transaction not subject to, the registration requirements under the Securities Act and in compliance with the securities legislation in the relevant state or any other jurisdiction of the United States. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States.

This press release contains certain forward-looking information that reflects Probi's present view of future events as well as financial and operational development. Words such as "intend", "assess", "expect", "may", "plan", "believe", "estimate" and other expressions entailing indications or predictions of future development or trends, not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information is not a guarantee of future results or development and actual outcomes may differ materially from the statements set forth in the forward-looking information.